• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity i

  2026-04-25

  This study demonstrates that MDM1 overexpression increases p53 expression and apoptosis, improving the response of colorectal cancer (CRC) cells to chemoradiotherapy. The findings highlight MDM1 as a predictive biomarker and potential therapeutic target for overcoming resistance in CRC treatment.

• Anlotinib Hydrochloride in Metastatic IADSRCT: Case Report I

  2026-04-24

  The referenced case report presents the first documented clinical use of anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor in metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT). The study demonstrates significant lymph node reduction and manageable toxicity, suggesting a new therapeutic avenue for this rare, aggressive tumor type.

• LY2228820: Precision p38 MAP Kinase Inhibition in Research W

  2026-04-24

  LY2228820, a highly selective p38 MAP kinase inhibitor from APExBIO, empowers researchers to dissect inflammation and angiogenesis with unprecedented specificity. Its dual-action mechanism and robust performance in apoptosis and anti-inflammatory assays set a new standard for experimental reliability.

• Docetaxel in Translational Research: Mechanisms, Resistance,

  2026-04-23

  Explore the mechanistic depth of Docetaxel (Taxotere) as a microtubule stabilization agent, its pivotal role in overcoming chemoresistance, and actionable strategies for translational researchers. This article synthesizes recent evidence—including MDR reversal via P-gp modulation—and provides protocol guidance, competitive insights, and a visionary outlook for advancing cancer chemotherapy research.

• Redefining mRNA Tracking: Dual-Mode Innovation for Translati

  2026-04-23

  This article explores the mechanistic advantages and strategic applications of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) for translational researchers. We dissect how Cap1 capping, 5-moUTP modification, and Cy5 labeling synergistically enable dual-modality tracking, enhanced translation, and immune evasion—positioning this tool at the vanguard of mRNA delivery and in vivo imaging. Drawing on new evidence for immune-modulatory delivery technologies, we offer practical protocol guidance and a forward-looking perspective on the evolving landscape of mRNA therapeutics.

• Metoprolol Tartrate: Mechanistic Precision in Cardiovascular

  2026-04-22

  This thought-leadership article explores how Metoprolol Tartrate, a selective β1-adrenergic blocking agent, is redefining experimental rigor in cardiovascular and translational research. By bridging mechanistic insights from recent studies on hematopoietic regeneration and clinical outcomes, the article delivers strategic guidance to researchers seeking precise, reproducible, and translatable results. APExBIO’s formulation is highlighted as a gold standard for β1-specific modulation, empowering scientific discovery and minimizing off-target effects.

• Annexin V-PE Apoptosis Detection Kit: Live-Cell Sensitivity

  2026-04-22

  Experience rapid, one-step apoptosis detection in live cells leveraging the specificity of Annexin V-PE and phosphatidylserine binding. This kit from APExBIO streamlines experimental workflows, supports robust quantitative analysis, and adapts seamlessly to cytometry and microscopy platforms for dynamic cell death studies.

• SP600125: JNK Inhibitor for Apoptosis and Inflammation Assay

  2026-04-21

  SP600125 stands out as a selective JNK inhibitor, enabling reproducible modulation of apoptosis and inflammation pathways in both cellular and animal models. With robust ATP-competitive inhibition and high selectivity, it supports advanced workflows in cytokine expression and translational research.

• Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe): Mechanisms

  2026-04-21

  Angiotensin II is a potent vasopressor and GPCR agonist, widely used in hypertension mechanism studies and vascular smooth muscle cell hypertrophy research. This article details its biological rationale, molecular mechanisms, and evidence-based protocols, referencing APExBIO’s research-grade product and peer-reviewed studies.

• Probenecid: Applied Workflows for Multidrug Resistance and N

  2026-04-20

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) empowers researchers to overcome multidrug resistance and achieve robust neuroprotection in ischemia models. This guide translates cutting-edge transporter biology into practical workflows, troubleshooting, and advanced applications for maximum reproducibility.

• KX2-391 Dihydrochloride: Translational Insights and Next Ste

  2026-04-20

  This article provides a strategic, evidence-driven guide for translational researchers leveraging KX2-391 dihydrochloride (Tirbanibulin dihydrochloride), a dual-mechanism inhibitor with robust applications in oncology, virology, and neurotoxin research. Blending mechanistic insights from recent SAR studies with actionable guidance, it details protocol parameters, cross-domain implications, and forward-looking perspectives, while situating APExBIO’s offering within the broader scientific landscape.

• Cefotaxime in Translational AMR Research: Mechanisms, Models

  2026-04-19

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, empowers translational antimicrobial resistance research with robust assay design and actionable insights. This article uniquely bridges molecular transmission data with advanced experimental applications.

• Commensal-Derived Phosphocholine Sugar Modulates Obesity via

  2026-04-18

  This study identifies a phosphocholine-modified exopolysaccharide from Clostridium immunis as a key microbiota-derived molecule that protects against obesity by regulating immunometabolic pathways. The research uncovers both the structural motif required for anti-obesity effects and the immunological mechanism, offering new avenues for metabolic disease intervention.

• Aneugen Mechanism Profiling: Insights from 27 Reference Chem

  2026-04-17

  Bernacki et al. introduce a two-tiered flow cytometry-based assay strategy to mechanistically classify aneugens by their molecular targets, examining 27 chemicals in TK6 cells. Their approach distinguishes tubulin binders from mitotic kinase inhibitors such as Aurora kinase inhibitors, offering a robust, machine learning–supported method to elucidate mechanisms underlying chemical-induced aneuploidy, with direct implications for cancer research and toxicological safety assessment.

• MK-1775 (Wee1 Kinase Inhibitor): Precision Tools for G2 Chec

  2026-04-16

  MK-1775 unlocks new avenues for selectively sensitizing p53-deficient tumor cells by precisely targeting the G2 DNA damage checkpoint. This article details actionable workflows, key protocol parameters, and troubleshooting guidance, synthesizing the latest reference findings and benchmarking APExBIO’s MK-1775 in advanced cancer research.

446 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page